|
 |
|
|||||||
|
|||||||||
© 2007 The American Thoracic Society
doi: 10.1513/pats.200703-041BR
Endpoints for Clinical Trials in Young Children with Cystic Fibrosis
1 Division of Pulmonology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 2 Department of Radiology, Cincinnati Children's Hospital, Cincinnati, Ohio; 3 Cystic Fibrosis Therapeutic Development Network Coordinating Center and Department of Biostatistics, University of Washington, Seattle, Washington; and 4 Division of Pulmonary Medicine, Children's Hospital and Regional Medical Center and Department of Pediatrics, University of Washington, Seattle, Washington
Correspondence and requests for reprints should be addressed to Stephanie D. Davis, M.D., Division of Pediatric Pulmonology, 130 Mason Farm Road, Campus Box 7220, Chapel Hill, NC 27599-7220. E-mail: sddavis{at}med.unc.edu
ABSTRACT
The availability of sensitive, reproducible, and feasible outcome measures for quantifying lung disease in children with cystic fibrosis (CF) younger than 6 years is critical to the conduct of clinical trials in this important population. Historically, identifying and quantifying the presence of lung disease in very young children with CF was hampered by a lack of reproducible measures of lung function or lung pathology. Over the past 10 years, significant progress has led to physiologic, anatomic, and bronchoscopic measures that may serve as endpoints for future intervention trials. These endpoints include infant and preschool lung function testing, computed tomography of the chest, and bronchoalveolar lavage markers of inflammation and infection. Much progress has occurred in standardizing lung function testing, which is essential for multicenter collaboration. Pulmonary exacerbation has the potential to serve as a clinical endpoint; however, there is currently no standardized definition in children with CF younger than 6 years. Further development of these outcomes measures will enable clinical trials in the youngest CF population with the objective of improving long-term prognosis.
Key Words: infant • child, preschool • respiratory function tests, computed tomography scanners, X-ray • bronchoalveolar lavage
Related articles in Proceedings of the American Thoracic Society:
- Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
- Nicole Mayer-Hamblett, Bonnie W. Ramsey, and Richard A. Kronmal
Proceedings of the American Thoracic Society 2007 4: 370-377.[Abstract] [Full Text] - Patient-reported Outcomes in Cystic Fibrosis
- Christopher H. Goss and Alexandra L. Quittner
Proceedings of the American Thoracic Society 2007 4: 378-386.[Abstract] [Full Text] - Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease
- Scott D. Sagel, James F. Chmiel, and Michael W. Konstan
Proceedings of the American Thoracic Society 2007 4: 406-417.[Abstract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  B. M. Linnane, G. L. Hall, G. Nolan, S. Brennan, S. M. Stick, P. D. Sly, C. F. Robertson, P. J. Robinson, P. J. Franklin, S. W. Turner, et al. Lung Function in Infants with Cystic Fibrosis Diagnosed by Newborn Screening Am. J. Respir. Crit. Care Med., December 15, 2008; 178(12): 1238 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Davis and F. Ratjen Reduced Lung Function in Cystic Fibrosis: A Primary or Secondary Phenotype? Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Ramsey Outcome Measures for Development of New Therapies in Cystic Fibrosis: Are We Making Progress and What Are the Next Steps? Proceedings of the ATS, August 1, 2007; 4(4): 367 - 369. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Sagel, J. F. Chmiel, and M. W. Konstan Sputum Biomarkers of Inflammation in Cystic Fibrosis Lung Disease Proceedings of the ATS, August 1, 2007; 4(4): 406 - 417. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
